US 12,226,397 B2
Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
Carmelita Frondoza, Edgewood, MD (US); Todd R. Henderson, Edgewood, MD (US); and Reinhard Grzanna, Woodstock, MD (US)
Assigned to NUTRAMAX LABORATORIES, INC., Lancaster, SC (US)
Filed by NUTRAMAX LABORATORIES, INC., Lancaster, SC (US)
Filed on Oct. 17, 2019, as Appl. No. 16/655,931.
Application 16/655,931 is a continuation of application No. 15/243,171, filed on Aug. 22, 2016, granted, now 10,485,784.
Application 15/243,171 is a continuation of application No. 13/112,488, filed on May 20, 2011, granted, now 9,421,234.
Prior Publication US 2020/0046681 A1, Feb. 13, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/385 (2006.01); A61K 9/00 (2006.01); A61K 36/48 (2006.01); A61K 36/54 (2006.01)
CPC A61K 31/385 (2013.01) [A61K 9/0053 (2013.01); A61K 36/48 (2013.01); A61K 36/54 (2013.01)] 14 Claims
 
1. An orally administrable composition for treating or reducing damage to connective tissue in a human in need thereof or for treating or reducing inflammatory symptoms associated with damage to connective tissue in the human in need thereof, comprising a synergistic combination of:
(i) avocado/soybean unsaponifiables, wherein the avocado/soybean unsaponifiables is in a daily dosage amount of from about 1 mg/kg body weight of the human/day to about 12 mg/kg body weight of the human/day; and
(ii) lipoic acid, a salt of lipoic acid, or a derivative of lipoic acid, wherein the lipoic acid, the salt of lipoic acid, or the derivative of lipoic acid, is in a daily dosage amount of from about 0.25 mg/kg body weight of the human/day to about 50 mg/kg body weight of the human/day, wherein a combination of (I) the avocado/soybean unsaponifiables and (II) the lipoic acid, the salt of lipoic acid, or the derivative of lipoic acid, provides a synergistic effect.